Longitudinal follow-up study of the retrobulbar and intrarenal hemodynamics in patients with T2DM

He Tai1,a,*, Xiao-lin Jiangb, Jin-song Kuangc, Yu-feng Yangd, Nan Songa, JJ JiaJia Yua, Yong Cuia, Ying Du, Yao Wu, Han-wen Zhangd, Xin-yue Cuia, Na Li, Li-de Zhangd, Xin Fug, Lian-qun Jia, Guan-lin Yang,a,∗

Abstract

Objective: The primary aim of this study is to examine the hemodynamics of retrobulbar and intrarenal in the changes of early stage of type 2 diabetes mellitus (T2DM) patients from 2000 to 2015 and to assess incidence associated with diabetic kidney disease (DKD) and diabetic retinopathy (DR).

Method: Our study contained 60 subjects newly diagnosed of T2DM were divided into 2 groups based on the mean resistive index (RI) (<0.7 and >0.7) of hemodynamic and to compare between-group differences of the early changes in hemodynamics of retrobulbar and intrarenal. And to conclude the incidences of diabetic kidney disease (DKD) and diabetic retinopathy (DR) subsequently with a long follow-up duration (2000–2015). First, to compare the mean RI of central retinal artery (CRA) between 2 groups. Second, to compare the mean RI of intrarenal hemodynamics in the bilateral interlobular renal arteries, renal function parameters (blood urea nitrogen (BUN), creatinine (Cr), blood glucose parameters (glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FBG), and 2-hour postprandial blood glucose (2hPBG)), glomerular filtration rate (GFR), albumin excretion rate (AER), and urine albumin-to-creatinine ratio (UACR) between 2 groups.

Results: First part of our follow-up studies was to compare hemodynamic RI index of retrobulbar in years of 2000 and 2015, both renal function and blood glucose parameters were fund significantly enhanced in subject group RIs <0.7. Incidence of DKD and DR was notably lower in group RIs <0.7 than group RIs >0.7, difference was statistically significant (P <.05). Incidence of HbA1c ≤7% was higher in group RIs <0.7 than group RIs >0.7, but difference was not statistically significant (P >.05). Incidence of proliferative diabetic retinopathy (PDR) was notably lower in group RIs <0.7 than group RIs >0.7, but the difference was not statistically significant (P >.05). Second part of our follow-up studies was to compare hemodynamic RI index of interlobular renal in years of 2000 and 2015, both renal function and blood glucose parameters were fund significantly enhanced in subject group RIs <0.7. Compared data of various incidences from first part of study were coherent with second part. (Incidence of DKD and DR was notably lower in group RIs <0.7 than group RIs >0.7, difference was statistically significant (P <.05). Incidence of HbA1c ≤7% was higher in group RIs <0.7 than group RIs >0.7, but difference was not statistically significant (P >.05). Incidence of PDR was notably lower in group RIs <0.7 than group RIs >0.7, but the difference was not statistically significant (P >.05).

Conclusions: RIs of retrobulbar and interlobular renal which would serve as a good predictors for the hemodynamics changes in retrobulbar and intrarenal would assess incidence of DKD and DR during the preclinical stage in long-term range excluding renal function and Hba1c in T2DM patients.

Abbreviations: 2hPBG = 2-hour postprandial blood glucose, AER = albumin excrete rate, AGEs = advanced glycated end-products, BP = blood pressure, BUN = blood urea nitrogen, CDI = color Doppler imaging, CMECs = cardiac microvascular endothelial cells, Cr = creatinine, CRA = central retinal artery, DBP = diastolic blood pressure, DKD = diabetic kidney disease, DN = diabetic nephropathy, GFR = glomerular filtration rate, HbA1c = glycosylated hemoglobin A1c, RIs = resistive index, RI = resistive index, UACR = urine albumin-to-creatinine ratio, VEGF = vascular endothelial growth factor.
1. Introduction

The incidence and prevalence of diabetes mellitus have increased remarkably worldwide, primarily due to the increasing incidence of type 2 diabetes mellitus (T2DM). Patients with T2DM develop abnormal glucose and lipid metabolism, which are associated with multiple organ dysfunction syndromes. Diabetes mellitus can cause complications such as diabetic retinopathy, diabetic nephropathy, and peripheral arterial disease.

2. Patients and methods

In our longitudinal follow-up studies, 154 subjects initially diagnosed with T2DM (82 males and 72 females) in year 2000 were divided into 2 groups based on the mean central retinal artery (CRA) and mean interlobular renal arteries hemodynamics (resistive index, RI) \( (\leq 0.7 \text{ and } >0.7) \). However, only 60 subjects (32 males and 28 females) could be allocated in 2015. The retrobulbar and intrarenal blood glucose (FBG, 2hPG, and HbA1c), RI, UACR, AER, BUN, and Cr were last measured in 2015 and compared to the values obtained in 2000. The diabetes duration (range: 4 to 12 years), glycated hemoglobin A1c (HbA1c) levels (range: 7.0% (53mmol/mol) to 10% (86mmol/mol), retrobulbar hemodynamic parameters (RI), renal function parameters (blood urea nitrogen (BUN) and creatinine (Cr) levels), albumin excretion rate (AER), urine albumin-to-creatinine ratio (UACR), and blood pressure (BP) were recorded. The end-stage renal disease (ESRD) was diagnosed in accordance with the guidelines of the American Diabetes Association[6]:

1. symptoms of diabetes (thirst, polydipsia, diuresis, and weight loss) that cannot be interpreted as any other pathology;
2. random plasma sugar (RPS) level \( \geq 11.1 \text{ mol/L} \), fasting plasma glucose (FPG) level \( \geq 7.0 \text{ mol/L} \), the outcome of the oral glucose tolerance test (OGTT) was a 2-hour postprandial plasma glucose (2hPG) level \( \geq 11.1 \text{ mol/L} \); or
3. an absence of symptoms of diabetes but the RPS level was \( \geq 11.1 \text{ mol/L} \) or the FPG level was \( \geq 7.0 \text{ mol/L} \).

DKD was confirmed according to US Kidney Disease Outcome Quality Initiatives (K/DOQI) guidelines (https://www.kidney.org/professionals/KDOQI/guidelines/commentaries). Based on the Fukuda classification, we evaluated the DR stage as follows: no signs of diabetic retinopathy-A0, nonproliferative diabetic retinopathy (mild)-A1, nonproliferative diabetic retinopathy (moderate)-A2, nonproliferative severe/preproliferative diabetic retinopathy-B1[7]. The DKD stage was evaluated categorically according to the AER levels in at least 2 of 3 timed urine collections: normal AER \( \leq 30 \text{ mg/24hour} \) or \( <20 \mu \text{g/minutes} \), microalbuminuria \( 30-300 \text{ mg/24hours} \) or \( 20-200 \mu \text{g/minutes} \), and macroalbuminuria \( >300 \text{ mg/24hours} \) or \( >200 \mu \text{g/minutes} \). The presence of ESRD was determined based on whether patients had undergone a kidney transplant or were receiving dialysis (patients with ESRD were excluded at baseline). The GFR was estimated with the formula based on cystatin C.[8] We used the NGSP converter to convert HbA1c levels from Diabetes Control and Complications Trial (DCCT)-derived units (%) to the units recommended by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) (mmol/mol) (http://www.ngsp.org/convert1.asp).

The selection criteria were:

1. patients diagnosed with T2DM by the guidelines of the American Diabetes Association[6];
2. had no history of smoking, pulmonary disease, cold, or pulmonary infection within a 2-week period;
3. were not diagnosed with hepatopathy, nephropathy, hyperuricemia, or gastrointestinal disease;
4. were likely to have good compliance and were able to visit our hospital for periodic assessments.
The change of RI in the CRA from baseline to year 15.

| Content | Group (mean RI in CRA) | ≤ 0.7 | > 0.7 | \( \chi^2 \) value | P value |
|---------|------------------------|-------|-------|----------------|---------|
| NO. (n) |                        | 25    | 35    |                |         |
| Sex, n (%) |                    | 13 (52.00) | 19 (54.29) | 0.031 | .861 |
| Age (years) in 2000 |                  | 52.44 ± 5.77 | 52.49 ± 5.64 | .031 | .976 |
| BMI (kg/m²) in 2000 |                   | 27.44 ± 1.36 | 27.31 ± 1.64 | .314 | .755 |
| Diabetes duration (years) in 2000 |           | 7.68 ± 2.12 | 7.23 ± 1.80 | .890 | .377 |
| HbA1c in 2000 |                       | 7.18 ± 0.35 | 7.79 ± 0.45 | 5.124 | .000* |
| Baseline HbA1c, n (%) in 2000 |               | < 7% (53 mmol/mol) | 6 (24.00) | 3 (8.57) | 2.723 | .009 |
| Baseline HbA1c, n (%) in 2015 |                | > 7% (33 mmol/mol) | 19 (76.00) | 32 (91.43) | 5.124 | .000* |
| FBG (mmol/l) |                        | 7.64 ± 0.38 | 8.09 ± 0.32 | 5.083 | .000* |
| 2 hPBG (mmol/l) |                      | 7.89 ± 0.42 | 8.26 ± 0.27 | 4.159 | .000* |
| DKO, n (%) in the 2015 |                | DKD | 6 (24.00) | 23 (65.71) | 10.162 | .001* |
| DR, n (%) in the 2015 |                 | NDR | 15 (60.00) | 11 (31.43) | .96 | .320 |
| Mean RI in interlobular renal arteries |           | baseline | 0.67 ± 0.03 | 0.75 ± 0.02 | 12.741 | .000* |
| Mean RI in CRA |                     | year 15 | 0.71 ± 0.03 | 0.80 ± 0.03 | 11.644 | .000* |
| AER |                        | baseline | 18.88 ± 1.48 | 19.97 ± 1.20 | 8.919 | .000* |
| UACR |                        | year 15 | 24.84 ± 7.06 | 35.00 ± 6.85 | 5.951 | .000* |
| Cr |                         | baseline | 16.04 ± 1.54 | 18.74 ± 1.24 | 7.507 | .000* |
| BUN |                         | year 15 | 27.10 ± 5.80 | 34.46 ± 5.82 | 4.741 | .000* |

* P < .05, the difference between the 2 groups had statistical significance.

AER = albumin excrete rate, BMI = body mass index, BUN = blood urea nitrogen, Cr = creatinine, DKO = diabetes kidney disease, DR = diabetic retinopathy, NDKD = no diabetes kidney disease, NDR = no diabetic retinopathy, NPDR = nonproliferative diabetic retinopathy, PDR = proliferative diabetic retinopathy, UACR = urinary albumin/creatinine ratio.

The exclusion criteria were
1. type 1 diabetes mellitus (T1DM), pregnancy, and lactation;
2. renal inadequacy, a serum Cr level >132 μmol/L for males or >123 μmol/L for females, AER >30 mg/24 hours or >20 mg/minute;
3. hyperhepatic, in which the liver enzyme levels are 2-fold higher than normal;
4. patients in intensive care receiving insulin treatment;
5. patients with both DR and hypertension (antihypertensive drugs were used);
6. patients with other eye conditions that may interfere with blood flow, such as maculopathy of any origin, glaucoma, high degree myopia, or patients with a history of laser treatment or intraocular surgery;
7. patients with both DKO and hypertension (antihypertensive drugs were used);
8. patients with other renal conditions that may interfere with blood flow, such as urolithiasis, urinary infections, and renal cysts (diameter >3 cm);
9. New York Heart Association class III or IV heart failure, a history of coronary angioplasty, coronary bypass surgery, coronary stent placement, or myocardial infarction within 6 months;
10. patients who use cholesterol-lowering drugs with inadequate control of the blood lipid levels (TC >250 mg/dl, HDL-C <30 mg/dl, LDL-C >170 mg/dl, and TG >200 mg/dl); and
11. patients who used systemically injected glucocorticoids within 3 months prior to our study.

This trial was conducted in accordance with the guidelines of the Declaration of Helsinki. The clinical research was approved by the Medical Ethics Committee (Number ICE20160204) at Shenyang the Fourth Hospital of People. The study protocol was reviewed by an independent ethics committee or institutional review board at every research site. Each patient and their family members provided written informed consent. Our research has been reviewed and registered on ClinicalTrials.gov (NCT02805543).
The change of RI in the retrobulbar blood vessels from baseline to year 15.

| Content                                                                 | Group (mean RI in interlobular renal arteries) | 0.7 | > 0.7 | t value | P value |
|------------------------------------------------------------------------|-----------------------------------------------|-----|-------|---------|---------|
| NO. (n)                                                               |                                               | 23  | 37    |         |         |
| Sex, n (%)                                                            |                                               |     |       |         |         |
| Male                                                                  | 12 (52.17)                                    | 20  | 54.05 | 0.031   | .861    |
| Female                                                                | 11 (47.83)                                    | 17  | 45.95 |         |         |
| Age (years) in 2000                                                    |                                               | 52.13±5.93 | 52.68±5.54 | 0.361   | .719    |
| BMI (kg/m²) in 2000                                                    |                                               | 27.43±1.41 | 27.32±1.60 | 0.272   | .787    |
| Diabetes duration (years) in 2000                                      |                                               | 7.65±2.21 | 7.27±1.76 | 0.741   | .462    |
| HbA1c in 2000                                                          |                                               | 7.22±0.34 | 7.76±0.46 | 4.852   | .000    |
| mmol/mol                                                               |                                               | 51.60±3.68 | 57.51±5.06 | 4.852   | .000    |
| HbA1c in 2015                                                          |                                               | 7.45±0.37 | 8.02±0.51 | 4.696   | .000    |
| mmol/mol                                                               |                                               | 54.07±4.06 | 60.38±5.57 | 4.696   | .000    |
| Baseline HbA1c, n (%) in 2000                                          |                                               |      |       |         |         |
| ≤ 7% (53 mmol/mol)                                                    |                                               | 5 (21.74) | 4 (10.61) | 1.329   | .249    |
| > 7% (53 mmol/mol)                                                    |                                               | 18 (78.26) | 33 (89.19) |         |         |
| Baseline HbA1c, n (%) in 2015                                          |                                               |      |       |         |         |
| ≤ 7% (53 mmol/mol)                                                    |                                               | 2 (8.70) | 2 (5.41) | 0.247   | .619    |
| > 7% (53 mmol/mol)                                                    |                                               | 21 (91.30) | 35 (94.59) |         |         |
| FBG (mmol/l)                                                          |                                               | 7.62±0.36 | 8.08±0.34 | 4.957   | .000    |
| year 15                                                               |                                               | 7.86±0.40 | 8.26±0.28 | 4.539   | .000    |
| 2 hPBG (mmol/l)                                                       |                                               |      |       |         |         |
| baseline                                                               |                                               | 11.17±0.72 | 12.30±0.56 | 3.462   | .001    |
| year 15                                                               |                                               | 12.15±0.76 | 12.67±0.60 | 2.971   | .004    |
| DKD, n (%) in the 2015                                                 |                                               |      |       |         |         |
| D KD                                                                  |                                               | 6 (26.09) | 23 (62.16) | 7.392   | .007    |
| N DKD                                                                 |                                               | 17 (73.91) | 14 (37.84) |         |         |
| DR, n (%) in the 2015                                                 |                                               |      |       |         |         |
| D R                                                                   |                                               | 9 (39.13) | 25 (67.57) | 4.671   | .031    |
| N DR                                                                  |                                               | 14 (60.87) | 12 (32.43) |         |         |
| PDR, n (%) in the 2015                                                 |                                               |      |       |         |         |
| P DR                                                                  |                                               | 1 (12.50) | 9 (56.00) | 1.585   | .208    |
| N PDR                                                                |                                               | 7 (87.50) | 16 (44.00) |         |         |
| Mean RI in interlobular renal arteries                                 |                                               |      |       |         |         |
| baseline                                                               |                                               | 0.67±0.02 | 0.75±0.02 | 14.405   | .000    |
| year 15                                                               |                                               | 0.71±0.03 | 0.79±0.03 | 10.820   | .000    |
| Mean RI in CRA                                                        |                                               |      |       |         |         |
| baseline                                                               |                                               | 0.67±0.03 | 0.74±0.02 | 11.650   | .000    |
| year 15                                                               |                                               | 0.71±0.03 | 0.79±0.03 | 9.862    | .000    |
| AER                                                                   |                                               |      |       |         |         |
| baseline                                                               |                                               | 16.96±1.49 | 19.76±1.50 | 7.050   | .000    |
| year 15                                                               |                                               | 25.17±7.27 | 34.24±7.40 | 4.648   | .000    |
| UACR                                                                  |                                               |      |       |         |         |
| baseline                                                               |                                               | 16.09±1.59 | 18.57±1.42 | 6.266   | .000    |
| year 15                                                               |                                               | 27.28±4.92 | 34.00±4.96 | 4.192    | .000    |
| Cr                                                                    |                                               |      |       |         |         |
| baseline                                                               |                                               | 74.43±5.59 | 75.11±4.22 | 0.639   | .508    |
| year 15                                                               |                                               | 87.70±7.58 | 92.03±5.34 | 2.595   | .122    |
| BUN                                                                   |                                               |      |       |         |         |
| baseline                                                               |                                               | 5.53±0.60 | 5.85±0.40 | 2.498   | .015    |
| year 15                                                               |                                               | 6.48±0.48 | 6.73±0.48 | 1.998   | .048    |

*P < .05, the difference between the 2 groups had statistical significance.

AER = albumin excretion rate, BMI = body mass index, BUN = blood urea nitrogen, Cr = creatinine, DKD = diabetes kidney disease, DR = diabetic retinopathy, NDKD = no diabetes kidney disease, NDR = no diabetic retinopathy, NPDR = nonproliferative diabetic retinopathy, PDR = proliferative diabetic retinopathy, UACR = urinary albumin/creatinine ratio.

2.1. Major equipment

A Logiq 400 MD Pro Series scanner (GE Medical Systems, Milwaukee, WI) with a 3.5-4 MHz vector array transducer, and a Powervision SSA-380A (Toshiba, Tokyo, Japan) with a 7 MHz transducer were used for the CDI recordings.

2.2. Study assessments and endpoints

Blood specimen collection and laboratory tests: Venous blood was extracted between 6–8 AM following a fast of ≥8 hours and was used to measure the levels of FPG. HbA1c; the glucose oxidase method was used to determine plasma glucose levels. For the OGTT, subjects were orally administered 75g of glucose (a 50% anhydrous glucose solution in 150 ml of warm water in 7.5 bottles). Venous blood was collected to measure the 2hPG; 5 ml of venous blood were collected in a glass tube and incubated for at least 10 minutes, centrifuged (3000 t/minute) for 10 minutes, and then the serum was separated, which was stored in a –70°C cryogenic refrigerator. BUN, and Cr levels were measured according to the manufacturer’s instructions. All specimens were measured within 1 week of collection.

Urine sample collection and laboratory tests: Urine parameters were quantified using a single 24-hour urine sample. We measured the urinary albumin concentration using a double antibody radioimmunoassay with a sensitivity of 0.5 mg/L, an intra-assay coefficient of variation of 4.5%, and an inter-assay coefficient of variation of 5.3% in the range of 10 to 50 mg/L. None of the patients with diabetes exhibited persistent microalbuminuria (defined as an AER greater than 20 μg/minute in 2 out of 3 overnight urine collections within 6 months).

Measuring BP: Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured using an electronic sphygmomanometer. Each subject’s BP was measured in a sitting position by placing an automatic device at the brachial artery after a 5-minute resting period.

Hemodynamic parameters of retrobulbar and intrarenal (PSV, EDV, and RI) in bilateral retrobulbar blood vessels (central retinal artery (CRA)) and interlobular renal arteries: The parameters were detected using CDI, bilateral CRA and
interlobular renal arteries were examined in the present study. Patients were measured in a sitting position, as described in a previous study.\textsuperscript{[9,10]} The measurements were conducted in patients who had fasted for at least 8 hours after documenting the BP and pulse rate. The examinations were initiated 15 minutes after the patients rested in the supine position, as described previously. The PSV and peak ESV were recorded in centimeters per second. Subsequently, we calculated the RI \((\text{PSV–EDV}/\text{PSV})\) for each vessel measured using a computer. These procedures were performed by the same ophthalmologist. For each recording, the RI was exclusively measured when at least 3 consecutive waveforms with a similar appearance were recorded. The mean value of 3 measurements was obtained for each patient. All examinations were performed twice by the same operator who had no knowledge of all the patients.

2.3. Statistical analysis

Data are presented as the means ± standard deviations (SD). The statistical analysis was conducted using the SPSS statistical package (Version 17.0, SPSS Inc. Chicago, IL, USA). Differences in categorical variables between the 2 groups were evaluated using the independent-samples t test; before and after treatment within-group differences in continuous variables between the 2 groups were evaluated using the independent-samples t test. Before and after treatment within-group differences in continuous variables were assessed using the paired-sample t test. \(P < .05\) was considered statistically significant.

3. Results

First part of longitudinal follow-up studies of the retrolubar hemodynamics of the 2 subject groups categorized by their RIs, significantly better renal function parameters (BUN and Cr), AER, UACR, and blood glucose (FBG, 2hPBG, and HbA1c) were observed in subjects with RIs \(\leq 0.7\) in 2000 and 2015. The incidence of HbA1c \(\leq 7\%\) in the group with RIs \(\leq 0.7\) (6/25, 24.00\%) was higher than that in the group with RIs \(>0.7\) (3/35, 8.57\%), but the difference was not statistically significant \((P > .05)\) in 2000; the incidence of HbA1c \(\leq 7\%\) in the group with RIs \(\leq 0.7\) (2/25, 8.00\%) was higher than that in the group with RIs \(>0.7\) (2/35, 5.71\%), but the difference was not statistically significant \((P > .05)\) in 2015. The incidence of DKD in the group with RIs \(\leq 0.7\) (6/25, 24.00\%) was significantly lower than that in the group with RIs \(>0.7\) (23/35, 65.71\%) \((P < .05)\). The incidence of DR was significantly lower in the group with RIs \(\leq 0.7\) (10/25, 40.00\%) than in the group with RIs \(>0.7\) (24/35, 68.57\%) \((P < .05)\). The incidence of proliferative diabetic retinopathy (PDR) was significantly lower in the group with RIs \(\leq 0.7\) (2/20, 10.00\%) than in the group with RIs \(>0.7\) (9/24, 37.50\%), but the difference was not statistically significant \((P > .05)\) (Table 1).

In the second longitudinal follow-up study of the interlobular renal hemodynamics of the 2 subject groups categorized by their RIs, significantly better renal function parameters (BUN and Cr), AER, UACR, and blood glucose (FBG, 2hPBG, and HbA1c) were observed in subjects with RIs \(\leq 0.7\) in 2000 and 2015. The incidence of HbA1c \(\leq 7\%\) in the group with RIs \(\leq 0.7\) (5/23, 21.74\%) was higher than that in the group with RIs \(>0.7\) (4/37, 10.81\%), but the difference was not statistically significant \((P > .05)\) in 2000; the incidence of HbA1c \(\leq 7\%\) in the group with RIs \(\leq 0.7\) (2/25, 8.70\%) was higher than that in the group with RIs \(>0.7\) (2/35, 5.41\%), but the difference was not statistically significant \((P > .05)\) in 2015. The incidence of DKD in the group with RIs \(\leq 0.7\) (6/23, 26.09\%) was significantly lower than that in the group with RIs \(>0.7\) (23/37, 62.16\%) \((P < .05)\). The incidence of DR was significantly lower in the group with RIs \(\leq 0.7\) (9/23, 39.13\%) than in the group with RIs \(>0.7\) (23/37, 67.57\%) \((P < .05)\). The incidence of proliferative diabetic retinopathy (PDR) was significantly lower in the group with RIs \(\leq 0.7\) (1/8, 12.50\%) than in the group with RIs \(>0.7\) (9/25, 36.00\%), but the difference was not statistically significant \((P > .05)\) (Table 2).

4. Discussion

Based on the results of the present study, RIs of retrolubar and intrarenal may serve as a good hemodynamic predictors of the changes in retrolubar and intrarenal in addition to GFR and it is considered a better predictor than UACR and AER in T2DM adult patients during the preclinical stage of DKD and DR. Strategies is to regulate glycemia which not only improve intrarenal hemodynamics but also improve retrolubar hemody-namics.

HbA1c is an indicator of diabetes control. The higher the HbA1c level, the poorer the diabetic control and the higher the circulating glucose concentration. If the circulating glucose concentration is consistently elevated for 3 months (as measured by HbA1c levels), an increase in the nonenzymatic glycosylation of tissue proteins may occur.\textsuperscript{[11]} Our results are consistent with the results of other studies, although the current study enrolled patients with HbA1c levels as low as 7.0\% (53 mmol/mol), whereas patients with baseline HbA1c levels <7.5\% (58 mmol/mol) were excluded in other studies.\textsuperscript{[11]} The difference is significant because of the seemingly greater efficacy of antidiabetic agents in patients with higher baseline HbA1c levels.\textsuperscript{[11]} A major factor contributing to poor compliance in maintaining HbA1c levels <7\% (53 mmol/mol) is a lack of patient awareness.\textsuperscript{[12]} As shown in the study by Prabhu et al,\textsuperscript{[12]} only 23 patients (11.5\%) were aware of their HbA1c levels, 10 patients (5\%) misinterpreted the HbA1c levels, and approximately 164 patients (82\%) were not aware of the significance of or the terminology for HbA1c. The proportion of patients with DR who achieved the target level of <7\% (53 mmol/mol) remained low. In our study, the proportion of patients (11/90; 12.22\%) reaching this standard HbA1c level [<7.0\% (53 mmol/ mol)] was also low; most patients did not adequately control their glycemia. Thus, the mean FPG (8.00 mmol/L) and 2hPG (11.58 mmol/L) levels were higher than the target levels (7 mmol/L and 10 mmol/L, respectively) in the diabetes group.

Renal Doppler RI is widely applied to evaluate blood flow in patients with renal parenchymal diseases. RI is generally accepted as a measure to quantify the changes in renal blood flow caused by renal disease. Thus, intrarenal vascular resistance is reflected and remarkably linked to vascular compliance (i.e., the rate of change in the volume of a vessel as a function of pressure).\textsuperscript{[15]} Additionally, the application of the captopril test to renal Doppler sonography in screening studies is a noninvasive and inexpensive tool for diagnosing renovascular hypertension.\textsuperscript{[13]} Therefore, we evaluated intrarenal hemodynamics by examining the RI using Doppler sonography.

DKD is typically responsible for end-stage renal disease (ESRD) in developed nations, which is thought to be attributable to interactions between metabolic and hemodynamic factors. Specific, metabolically driven, glucose-dependent pathways are
activated within the renal tissues of patients with diabetes. These pathways trigger oxidative stress, hexosamine flux, polyol pathway flux, and the accumulation of advanced glycation endproducts (AGEs). Hemodynamic factors are also involved in the pathogenesis of DKD; the pathophysiological mechanism of DKD poses a substantial challenge to medical researchers.[13]

Despite the unclear nature of the exact pathogenesis of the disease, several theories have been proposed regarding the processes affecting hemodynamics in DKD. Researchers have focused on the hemodynamic changes in the diabetic kidney. Activation of the renin-angiotensin system (RAS) has been reported to induce abnormalities in intrarenal hemodynamics in patients with diabetes.[14] According to Taniwaki and colleagues, the intrarenal RAS might be activated in patients with diabetes; however, the activation might be impacted by poor glycemic control. In addition, blockade of RAS activation with captopril might reduce intrarenal vascular resistance in patients with diabetes.[15]

Elevated RI has been reported to be associated with vascular-interstitial disease, including DKD (with the exception of glomerulopathies), which might be caused by decreased tissue and vascular compliance, as well as by increased vascular resistance.[19] However, early stages of DN are related to an increased GFR and variable increases in renal plasma flow and filtration fraction in both clinical and experimental settings. Diabetic hyperperfusion and hyperfiltration at the single-nephron level are characterized by a disproportionate decrease in apparent arteriolar resistance, leading to an elevation of the glomerular capillary pressure. These features may also be reflected by an increase in RI.[16,18] Duplex Doppler sonography is a noninvasive and inexpensive tool used to measure the RI and identify hemodynamic abnormalities in patients with DKD during the preclinical stage.[17] Based on the results of biopsy studies using children, basement membrane thickening, and mesangial expansion in the kidney develop prior to the onset of microalbuminuria.[18] Evidently, Doppler sonography does not replace renal biopsy, but it provides a readily applicable and noninvasive tool to investigate renal hemodynamics. In addition, Doppler sonography is also a credible approach to provide both morphological and physiological data when studying renal blood flow in children.[16] To our knowledge, our study is the first to examine the early changes in intrarenal hemodynamics in adults with T2DM without any evidence of renal dysfunction. Although the renal function was normal in patients with diabetes; therefore, RI can be used to predict changes in renal function in the preclinical stage of DKD. Our results are similar to the results reported by Pelliccia P and colleagues, who selected children as study subjects.[16]

Nevertheless, a general agreement regarding the significance and the predictive value of renal RI in patients with DKD has not been achieved. Several published studies have examined the application of Doppler sonography in evaluating abnormalities in intrarenal hemodynamics in adults with DKD.[15,19] But studies of adults during the preclinical stage of DKD (with normal renal function) are still lacking. In our study, we aimed to explore whether Doppler sonography could be applied to detect alterations in renal RI in diabete adults who had normal renal function in laboratory tests. Although all RI values were less than or equal to 0.70 for both kidneys, the widely recognized boundary value is applied to healthy adults and children older than 6 years (rather than younger children).[20] The pathophysiological mechanism of DR poses a substantial challenge in medical science. Although the precise pathogenesis of the disease has not been described, several theories have been posed to describe the processes that impact ocular blood flow in DR. Several researchers have focused more on the hemodynamic changes in the diabetic retina and choroid. Ocular blood flow is measured as blood flow velocity multiplied by the cross-sectional area, as measured in other vascular beds. In terms of abnormalities in ocular blood flow at various stages of DR, some notable deviations were documented in different reports. However, the precise nature of the deviations remains somewhat controversial, presumably due to various techniques in measuring retinal blood flow.[21,22] Few research studies have assessed hemodynamic changes in patients without DR; thus, we studied the hemodynamic changes in T2DM patients without DR. Inhibiting progression to DR is the goal of the treatment period. DR is one of the main factors contributing to preventable blindness in developed nations and is becoming the primary factor responsible for blindness in middle-income nations.[23] Up to 39% of patients who receive a first diagnosis of T2DM are estimated to present with signs of DR.[24] Population-based diabetic eye screening programs have been initiated in several western European countries. The incidence and prevalence of blindness is reduced in patients with diabetes who have access to screening programs compared with populations in which organized, population-based screening has not been implemented.[25] However, population-based diabetic eye screening programs cannot be widely implemented in China because of the limited healthcare conditions compared to those in western European countries. The frequency of DR, a well-known microvascular complication of DM, increases with age and disease duration. An overwhelming majority of T1DM patients and over 60% of T2DM patients will develop DR within 20 years.[26] Because of the exclusion of DR and DKD, we chose patients with a diabetes duration ranging from 3 to 12 years (<15 years). CDI is used to evaluate circulatory parameters of retrobulbar blood vessels. Scanning laser Doppler flowmetry (SLDF), a useful method for evaluating blood flow in retinal tissues, has been widely applied in ophthalmic pathology for many years.[27,28]

Therefore, in our longitudinal follow-up study, the quantum was 15 years (from 2000 to 2015). As shown in the study by Dimitrova G, the results of a retinal tissue evaluation using SLDF were positively correlated with the retrobulbar circulatory parameters of CDI in diabetes patients without DR.[29] Dimitrova G also reported significantly increased PSV, EDV, and RI in CRV, due to the progression of retinopathy during a 21-month period, but no significant alterations in the circulatory parameters in the CRA or PCA were recorded after the progression of DR.[30] In our first part of follow-up study, the retrobulbar hemodynamics of the 2 subject groups categorized by their RIs indicated that subjects with RIs ≤0.7 showed significantly improved renal function parameters (BUN and Cr levels), AER, UACR, and blood glucose (FBG, 2hPBG, and HbA1c) in 2000 and 2015. The incidence of DKD was significantly lower in subject group RIs ≤0.7 (6/25, 24.00%) than group RIs >0.7 (23/45, 65.71%) (P<.05). The incidence of DR was significantly lower in group RIs ≤0.7 (10/25, 40.00%) than group RIs >0.7 (24/35, 68.57%) (P<.05). The incidence of PDR was significantly lower in group RIs ≤0.7 (2/20, 20.00%) than group RIs >0.7 (9/24, 37.50%), but the difference was not significant (P>.05) (Table 1). In our second longitudinal follow-up study of the interlobular renal
hemodynamics of the 2 subject groups categorized by their RIs, significantly better renal function parameters (BUN and Cr), AER, UACR, and blood glucose (FBG, 2hPBG, and HbA1c) were observed in subjects with RIs ≤0.7 in 2000 and 2015. The incidence of HbA1c ≤7% in subject groups RIs ≤0.7 (5/23, 21.74%) was higher than group RIs >0.7 (4/37, 10.81%), but the difference was not statistically significant (P >0.05). In 2000, the incidence of HbA1c ≤7% in group RIs ≤0.7 (2/23, 8.70%) was higher than group RIs >0.7 (2/37, 5.41%), but the difference was not statistically significant (P >0.05). The incidence of DKD in the group with RIs ≤0.7 (6/23, 26.09%) was significantly lower than that in the group with RIs >0.7 (23/37, 62.16%) (P <0.05). The incidence of DR was significantly lower in the group with RIs ≤0.7 (9/23, 39.13%) than in the group with RIs >0.7 (25/37, 67.57%) (P <0.05). The incidence of proliferative diabetic retinopathy (PDR) was significantly lower in the group with RIs ≤0.7 (1/8, 12.50%) than in the group with RIs >0.7 (9/25, 36.00%), but the difference was not statistically significant (P >0.05) (Table 2). The RIs increased gradually and significantly over period of 15 years, similar to the results reported in the 10-year follow-up study by Neudorfer.131

As shown in the study by Hirose A et al.,132 HbA1c levels may better predict retinopathy if metabolic memory-free data are included. In addition, some studies have reported a correlation between the severity of retinopathy and the extent of decreased blood flow. Hyperglycaemia enhances blood flow and interferes with retinal autoregulation. In addition, retinal blood flow is regulated by changes in ocular vascular resistance and the RI was notably higher in the diabetes than in the healthy people;133,134 therefore, RI plays an important role in assessing hemodynamic changes in DR patients.

In summary, the RI can be used to evaluate the hemodynamic changes of retrobulbar and intrarenal in DKD/DR and its progression and it can also predict hemodynamic changes in retrobulbar and kidney during the preclinical stage of DR and DKD, similar to the HbA1c levels and diabetes duration.

In our future study, several concerns shall be addressed as follow. First, we could not observe the morphological changes in retinal and renal tissues and did not identify the protein that induced damage to these tissues. Because not all patients agree to undergo a biopsy, we will adopt an animal model to study the pathology. Second, we did not assess the long-term changes, and we only examined the index in the early period (without DKD and DR). Third, we studied patients with T2DM during the preclinical stage and did not study them at different stages of DKD and DR. Moreover, retrobulbar, and intrarenal IR may have been used as the as good predictors of ophthalmic diseases and nephropathy, these studies will been carried out in the future.

In conclusion, this study is anticipated as the first to use the RI to predict the progression of DKD and DR. For patient’s lack of proper control of glycemia, RI of retrobulbar and intrarenal can predict the degree of damages to hemodynamic during the treatment which include patients not presented with DKD and DR. Therefore, retinal and kidney function should be monitored by both doctors and patients during the preclinical stage of diabetes.

Author contributions

Data curation: Ying Du, Han-wen Zhang, Xin-yue Cui, Xin Fu. Funding acquisition: Xin Fu, Guan-lin Yang. Investigation: Ying Du, Yao Wu, Han-wen Zhang, Xin-yue Cui.

Methodology: Yu-feng Yang, Nan Song, Yong Cui, Ying Du, Xin-yue Cui, Xin Fu.

Project administration: Xin-yue Cui.

Resources: Jin-song Kuang, Yu-feng Yang, Nan Song, Yong Cui, Ying Du.

Supervision: Na Li, Guan-lin Yang.

Validation: Lian-qun Jia.

Visualization: Guan-lin Yang.

Writing – original draft: He Tai, Xiao-lin Jiang, Lian-qun Jia.

Writing – review & editing: Xiao-lin Jiang, JJ JiaJia Yu, Li-de Zhang, Lian-qun Jia, Guan-lin Yang.

References

[1] Malone JI, Morrison AD, Pavan PR, et al. Prevalence and significance of retinopathy in subjects with type 1 diabetes of less than 5 years’ duration screened for the Diabetes Control and Complications Trial. Diabetes Care 2001;24:522–6.

[2] de Boer IH, Rue TC, Hall YN, et al. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011;305:2532–9.

[3] Yamagishi S, Fukami K, Matsu T. Crosstalk between advanced glycation end products (AGEs)-receptor RAGE axis and dipeptidyl peptidase-4-incretin system in diabetic vascular complications. Cardiovasc Diabetol 2015;14:2.

[4] Lieb WE, Cohen SM, Merton DA, et al. Color Doppler imaging of the eye and orbit: technique and normal vascular anatomy. Arch Ophthalmol 1991;109:527–31.

[5] Tublin ME, Bude RO, Platt JF. The resistive index in renal Doppler sonography: where do we stand? AJR Am J Roentgenol 2003;180:885–92.

[6] American Diabetes AssociationStandards of medical care in diabetes 2007. Diabetes Care 2011;34(Suppl 1):S11–61.

[7] Fujikura M. Classification and treatment of diabetic retinopathy. Diabetes Res Clin Pract 1994;24(Suppl 1):S171–6.

[8] Stevens LA, Coresh J, Schmid GH, et al. Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 2008;51:395–406.

[9] Dimmtruga G, Kato S, Tamaki Y, et al. Coroidal circulation in diabetic patients. Eye 2001;15(Pt 5):602–7.

[10] Fruachiger B, Nussbaumer P, Hugentobler M, et al. Duplex sonographic registration of age and diabetes-related loss of renal vasodilatory response to nitroglycerine. Nephrol Dial Transplant 2000;15:827–31.

[11] Lukashevich V, Del Prato S, Araga M, et al. Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea. Diabetes Obes Metab 2014;16:403–9.

[12] Prabhu M, Kakhandaki A, Chandra KR, et al. A hospital based study regarding awareness of association between glycosylated haemoglobin and severity of diabetic retinopathy in type 2 diabetic individuals. J Clin Diagn Res 2016;10:NC04–5.

[13] Veglio F, Francisco M, Melchio R, et al. Assessment of renal resistance index after captopril test by Doppler in essential and renovascular hypertension. Kidney Int 1995;48:1611–6.

[14] Miller JA. Impact of hyperglycaemia on the renin angiotensin system in early human type 1 diabetes mellitus. J Am Soc Nephrol 1999;10:1778–85.

[15] Taniwaki Hi, Ishimura E, Kawagishi T, et al. Intrarenal hemodynamic changes after captopril test in patients with type 2 diabetes: a duplex Doppler sonography study. Diabetes Care 2005;28:132–7.

[16] Pelliccia P, Savino A, Cecamore C, et al. Early changes in renal hemodynamics in children with diabetes: doppler sonographic findings. J Clin Ultrasound 2008;36:335–40.

[17] Matsumoto N, Ishimura E, Taniwaki H, et al. Diabetes mellitus worsens intrarenal hemodynamic abnormalities in non-dialyzed patients with chronic renal failure. Nephron 2000;86:44–51.

[18] Ellis EN, Warady BA, Wood EG, et al. Renal structural-functional relationships in early diabetes mellitus. Pediatr Nephrol 1997;11:584–7.

[19] Ohya Y, Fujii K, Arima H, et al. Increased renal resistive index in atherosclerosis and diabetic nephropathy assessed by Doppler sonography. J Hypertens 2005;23:1905–10.
[20] Kuzmic AC, Brkljacic B, Ivankovic D, et al. Doppler sonographic renal resistive index in healthy children. Eur Radiol 2000;10:1644–50.
[21] Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye (Lond) 2009;23:1496–508.
[22] Pemp B, Schmetterer L. Ocular blood flow in diabetes and age-related macular degeneration. Can J Ophthalmol 2008;43:295–301.
[23] Resnikoff S, Pascolini D, Etya’ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ 2004;82:844–51.
[24] Pemp B, Schmetterer L. Ocular blood flow in diabetes and age-related macular degeneration. Can J Ophthalmol 2008;43:295–301.
[25] Stefansson E, Bek T, Porta M, et al. Screening and prevention of diabetic retinopathy. Diabetes Care 1998;21:143–56.
[26] Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy – a systematic review. JAMA 2007;298:902–16.
[27] Michaelson G, Langhans MJ, Groh MJM. Clinical investigation of the combination of a scanning laser ophthalmoscope and laser Doppler flowmeter. Ger J Ophthalmol 1995;4:342–9.
[28] Michelson G, Langhans MJ, Groh MJM. Perfusion of the juxtapapillary retina and the neuroretinal rim area in primary open angle glaucoma. J Glaucoma 1996;5:91–8.
[29] Dimitrova G, Kato S, Fukushima H, et al. Circulatory parameters in the retrobulbar central retinal artery and vein of patients with diabetes and medically treated systemic hypertension. Graefes Arch Clin Exp Ophthalmol 2009;247:53–8.
[30] Dimitrova G, Kato S, Yamashita H, et al. Relation between retrobulbar circulation and progression of diabetic retinopathy. Br J Ophthalmol 2003;87:622–5.
[31] Neudorfer M, Kessner R, Goldenberg D, et al. Retrobulbar blood flow changes in eyes with diabetic retinopathy: a 10-year follow-up study. Clin Ophthalmol 2014;8:2325–32.
[32] Hirose A, Furushima D, Yamaguchi N, et al. Prediction of retinopathy at 20 years after onset in younger onset type 1 diabetes using mean-metabolic memory-free HbA1c values: the importance of using HbA1c data of total, not partial, diabetes duration. Diabetes Care 2013;36:3812–4.
[33] Güven D, Ozdemir H, Hasanreisoglu B. Hemodynamic alterations in diabetic retinopathy. Ophthalmology 1996;103:1245–9.
[34] Kawagishi T, Nishizawa Y, Emoto M, et al. Impaired retinal artery blood flow in IDDM patients before clinical manifestations of diabetic retinopathy. Diabetes Care 1995;18:1544–9.